300 related articles for article (PubMed ID: 20890777)
1. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme.
Heimes B; Lommatzsch A; Zeimer M; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):639-44. PubMed ID: 20890777
[TBL] [Abstract][Full Text] [Related]
2. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome.
Gerding H; Loukopoulos V; Riese J; Hefner L; Timmermann M
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):653-62. PubMed ID: 21387180
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration.
Muether PS; Hoerster R; Hermann MM; Kirchhof B; Fauser S
Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):453-8. PubMed ID: 22573410
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab.
Calvo P; Ferreras A; Al Adel F; Wang Y; Brent MH
Br J Ophthalmol; 2015 Jun; 99(6):723-6. PubMed ID: 25425713
[TBL] [Abstract][Full Text] [Related]
5. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
6. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity.
Muether PS; Hermann MM; Koch K; Fauser S
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):633-7. PubMed ID: 20865421
[TBL] [Abstract][Full Text] [Related]
7. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
[TBL] [Abstract][Full Text] [Related]
8. Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes.
Saleh M; Kheliouen M; Tebeanu E; Ballonzoli L; Bourcier T; Speeg-Schatz C; Gaucher D
Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1901-7. PubMed ID: 23430191
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
11. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
Ophthalmology; 2014 May; 121(5):1092-101. PubMed ID: 24461586
[TBL] [Abstract][Full Text] [Related]
12. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K;
Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856
[TBL] [Abstract][Full Text] [Related]
13. Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care.
Reznicek L; Muhr J; Ulbig M; Kampik A; Mayer WJ; Haritoglou C; Neubauer A; Wolf A
Br J Ophthalmol; 2014 Oct; 98(10):1333-7. PubMed ID: 24903670
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.
Rouvas A; Petrou P; Vergados I; Pechtasides D; Liarakos V; Mitsopoulou M; Ladas I
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1609-16. PubMed ID: 19609550
[TBL] [Abstract][Full Text] [Related]
15. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
16. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
Cruz-Gonzalez F; Cabrillo-Estévez L; López-Valverde G; Cieza-Borrella C; Hernández-Galilea E; González-Sarmiento R
Graefes Arch Clin Exp Ophthalmol; 2014 Mar; 252(3):469-75. PubMed ID: 24522370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
